Short Summary
Google LLC filed an IPR petition seeking to invalidate all 15 claims of Sandpiper CDN’s ’322 patent covering CDN edge‑server selection. The petition relies on Verma and other prior‑art references under §§102 and 103.
Detailed Summary
In a petition for inter partes review, Google LLC challenges the validity of U.S. Patent No. 10,057,322 owned by Sandpiper CDN, LLC. The ’322 patent claims methods for selecting an edge server in a content delivery network and delivering modified embedded resources. Google contends that the patent’s claims are anticipated or obvious in light of the Verma publication and combinations of Verma with Raciborski, Lewin, and Drai, invoking statutory grounds under 35 U.S.C. §§102 and 103. The petition requests that the PTAB institute review and find all fifteen claims unpatentable, and includes a declaration from expert Todd C. Mowry, Ph.D. The proceeding is at the petition stage, with the Board’s discretionary factors under §§314 and 325 noted as favorable to institution.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Google LLC vs Sandpiper CDN, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Micron Technology, Inc. et al.vsYangtze Memory Technologies Company, Ltd.
Micron Technology successfully secured institution at the PTAB against Yangtze Memory Technologies regarding claims related to 3D memory devices. The Board found sufficient evidence for unpatentability under both §102 and §103 over prior art references Toyama, Mushiga, and Makala.
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
Miracor Medical seeks Director Review to deny Abbott’s institution of IPR 2025‑00115, arguing procedural deficiencies, lack of particularity, improper claim constructions, and word‑count violations. The Board had previously instituted the IPR on numerous cardiac‑pump claims.
Axion Biosystems, Inc.vsAgilent Technologies, Inc.
The PTAB issued a final decision finding the challenged claims unpatentable over Xu-752 and Jones. The Board concluded that the Petitioner failed to demonstrate non-hindsight motivation for combining the references or making the necessary technical modifications, citing lack of support for millisecond time resolution.
Dr. Falk Pharma GmbHvsEllodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Apple Inc.vsSmith Interface Technologies, LLC
The PTAB issued a Final Written Decision denying the petitioner's obviousness challenges against numerous claims of Smith Interface Technologies. The Board found that the asserted prior art combinations (Ahn and Chaudhri) failed to teach the specific functional limitations required by the patent claims, particularly regarding progressive gesture-based display transitions.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.